Our commitment to assisting members and providers through the many challenges faced during case surges and hospitalizations guided our business decision to continue the cost-share waiver for COVID-19 treatment for our fully insured members. Some of our self-funded groups also chose to extend the member cost-share waiver. 

Jubilant Cadista Pharmaceuticals Inc. is conducting a market recall at the wholesale level all quantities of all unexpired lots Losartan Potassium Tablets, USP and Losartan Potassium and Hydrochlorothiazide (HCTZ) Tablets, USP distributed under the Cadista label due to the presence of azido, a potential mutagenic impurity. Azido is considered a mutagen, which is a chemical substance that can cause a change in the DNA of a cell. These mutations may increase the risk of cancer, but the specific risk for this azido impurity to cause cancer in humans is unknown. 

The U.S. Food and Drug Administration (FDA) announced on September 16, 2021 that the drug manufacturer Pfizer is voluntarily recalling all lots of Chantix 0.5 mg and 1 mg tablets due to the presence of a nitrosamine, N-nitroso-varenicline, a probable human carcinogen (a substance that could cause cancer). As alternative suppliers have been approved in the United States, Pfizer is undertaking this precautionary measure.